Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Apply
Axicabtagene Ciloleucel & Radiotherapy
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step